Supplementary Material for TACE vs. TACE+S Meta-Analysis of HCC Trials

A meta-analysis and trial sequential analysis of 10 randomized controlled trials comprising 2,296 patients, published by figshare admin karger in 2026. The supplementary material evaluates the efficacy and safety of combining transarterial chemoembolization (TACE) with systemic therapy versus TACE alone for unresectable, non-metastatic hepatocellular carcinoma (HCC). The analysis includes hazard ratios for overall survival, progression-free survival, time to progression, and adverse events.

Use Cases

• Reviewing statistical evidence for TACE combination therapy based on the meta-analysis results
• Assessing adverse event profiles for combination therapy based on the safety analysis
• Evaluating subgroup analysis findings, such as the benefit for HBV-related HCC patients
• Examining trial sequential analysis methodology applied to clinical trial data

Strengths

• Analysis includes 10 randomized controlled trials with 2,296 patients
• Results include hazard ratios and confidence intervals for multiple outcomes like overall survival and time to progression
• Material is licensed under CC-BY-4.0 for open reuse

Limitations

• The dataset consists of PDF and DOCX files; the underlying tabular data is not directly accessible
• Column-level documentation is absent; field semantics must be inferred from the supplementary documents
• Row count is unknown, which may limit suitability assessment

Provenance

Source

figshare admin karger

Collection Method

Systematic search of major databases for randomized controlled trials

Freshness

Last updated 2026-04-29 05:55:26